[go: up one dir, main page]

TR199801801T2 - Madde kötüye kullaniminin tedavisi. - Google Patents

Madde kötüye kullaniminin tedavisi.

Info

Publication number
TR199801801T2
TR199801801T2 TR1998/01801T TR9801801T TR199801801T2 TR 199801801 T2 TR199801801 T2 TR 199801801T2 TR 1998/01801 T TR1998/01801 T TR 1998/01801T TR 9801801 T TR9801801 T TR 9801801T TR 199801801 T2 TR199801801 T2 TR 199801801T2
Authority
TR
Turkey
Prior art keywords
substance abuse
treatment
olanzapine
administering
patient
Prior art date
Application number
TR1998/01801T
Other languages
English (en)
Inventor
Merritt Beasley Charles
Kurt, (Nmn) Rasmussen
Dennis Tollefson Gary
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199801801T2 publication Critical patent/TR199801801T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Disintegrating Or Milling (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steroid Compounds (AREA)

Abstract

Bulus olan zapinin veya farmasötik olarak kabul edilebilir bir tuzunun etkili bir miktarinin memelilerde madde kötüye kullanimini tedavi etmeye yönelik bir ilacin imalatinda kullanimina iliskindir.
TR1998/01801T 1996-03-11 1997-03-10 Madde kötüye kullaniminin tedavisi. TR199801801T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1316096P 1996-03-11 1996-03-11
US1316196P 1996-03-11 1996-03-11
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse

Publications (1)

Publication Number Publication Date
TR199801801T2 true TR199801801T2 (tr) 1998-12-21

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01801T TR199801801T2 (tr) 1996-03-11 1997-03-10 Madde kötüye kullaniminin tedavisi.

Country Status (15)

Country Link
EP (1) EP1007050B1 (tr)
JP (1) JP2000517287A (tr)
KR (1) KR19990087714A (tr)
CN (1) CN1213308A (tr)
AT (1) ATE295731T1 (tr)
BR (1) BR9708037A (tr)
CA (1) CA2248738A1 (tr)
CZ (1) CZ290398A3 (tr)
DE (1) DE69733321D1 (tr)
IL (1) IL126158A0 (tr)
NO (1) NO984196L (tr)
NZ (1) NZ331845A (tr)
PL (1) PL328924A1 (tr)
TR (1) TR199801801T2 (tr)
WO (1) WO1997033586A1 (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757870B2 (en) * 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
DE69923081T2 (de) 1998-11-23 2005-12-08 Sepracor Inc., Marlborough Desmethylolanzapine enthaltende zusammensetzungen und verfahren
CA2434388C (en) * 2001-01-12 2012-08-21 Innovation Ventures, Llc Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
BR9708037A (pt) 1999-07-27
AU725940B2 (en) 2000-10-26
KR19990087714A (ko) 1999-12-27
DE69733321D1 (de) 2005-06-23
NZ331845A (en) 2000-09-29
WO1997033586A1 (en) 1997-09-18
NO984196D0 (no) 1998-09-11
ATE295731T1 (de) 2005-06-15
IL126158A0 (en) 1999-05-09
EP1007050A4 (en) 2000-06-14
CZ290398A3 (cs) 1999-10-13
CA2248738A1 (en) 1997-09-18
EP1007050B1 (en) 2005-05-18
EP1007050A1 (en) 2000-06-14
CN1213308A (zh) 1999-04-07
JP2000517287A (ja) 2000-12-26
NO984196L (no) 1998-11-03
PL328924A1 (en) 1999-03-01
AU2067297A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
GR3034508T3 (en) Use of insulin sensitizing agents to treat hypertension.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
TR199801801T2 (tr) Madde kötüye kullaniminin tedavisi.
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
BR9908190A (pt) Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente
DK0693912T3 (da) Apparat til medicinsk behandling
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
EA199800818A1 (ru) Способ лечения бессонницы
YU40198A (sh) Postupak za tretiranje zavisnosti od supstance
RU97110384A (ru) Способ лечения вибрационной болезни
DK0872238T3 (da) Anvendelse af olanzapin til fremstilling af et medikament til neuroprotektin
DE69828553D1 (de) Gerät zur behandlung von harnwegs- und anderen körperstenosen